Tangier disease

Tangier disease
ICD-10	E78.6
ICD-9	272.5
OMIM	205400
DiseasesDB	12901
MeSH	D013631

WikiDoc Resources for Tangier disease
Articles
Most recent articles on Tangier disease Most cited articles on Tangier disease Review articles on Tangier disease Articles on Tangier disease in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Tangier disease Images of Tangier disease Photos of Tangier disease Podcasts & MP3s on Tangier disease Videos on Tangier disease
Evidence Based Medicine
Cochrane Collaboration on Tangier disease Bandolier on Tangier disease TRIP on Tangier disease
Clinical Trials
Ongoing Trials on Tangier disease at Clinical Trials.gov Trial results on Tangier disease Clinical Trials on Tangier disease at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Tangier disease NICE Guidance on Tangier disease NHS PRODIGY Guidance FDA on Tangier disease CDC on Tangier disease
Books
Books on Tangier disease
News
Tangier disease in the news Be alerted to news on Tangier disease News trends on Tangier disease
Commentary
Blogs on Tangier disease
Definitions
Definitions of Tangier disease
Patient Resources / Community
Patient resources on Tangier disease Discussion groups on Tangier disease Patient Handouts on Tangier disease Directions to Hospitals Treating Tangier disease Risk calculators and risk factors for Tangier disease
Healthcare Provider Resources
Symptoms of Tangier disease Causes & Risk Factors for Tangier disease Diagnostic studies for Tangier disease Treatment of Tangier disease
Continuing Medical Education (CME)
CME Programs on Tangier disease
International
Tangier disease en Espanol Tangier disease en Francais
Business
Tangier disease in the Marketplace Patents on Tangier disease
Experimental / Informatics
List of terms related to Tangier disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

Tangier disease is a rare inherited disorder characterized by a severe reduction in the amount of high-density lipoprotein (HDL), often referred to as "good cholesterol," in the bloodstream. High-density lipoproteins are created when a type of protein in the bloodstream, apolipoprotein A1 (apoA1), picks up cholesterol from the cells. People with Tangier disease have a greatly reduced ability to transport cholesterol out of their cells, leading to a deficiency of high-density lipoproteins in the bloodstream and the accumulation of cholesterol in many body tissues. Reduced blood levels of high-density lipoproteins is sometimes described as hypolipoproteinemia.

People affected by this condition also have slightly elevated amounts of fat in the blood (mild hypertriglyceridemia) and disturbances in nerve function (neuropathy). The tonsils are visibly affected by this disorder; they frequently appear orange or yellow and are extremely enlarged. Affected people often develop premature atherosclerosis, which is characterized by fatty deposits and scar-like tissue lining the arteries. Other signs of this condition may include an enlarged spleen (splenomegaly), an enlarged liver (hepatomegaly), clouding of the clear covering of the eye (cornea), and early-onset cardiovascular disease.

Historical Perspective

Tangier disease (TD) is a genetic disorder of cholesterol transport named for the secluded island of Tangier, located off the coast of Virginia. TD was first identified in a five-year-old inhabitant of the island who had characteristic orange tonsils, very low levels of high density lipoprotein (HDL) or 'good cholesterol', and an enlarged liver and spleen.

Pathophysiology

Genetics

File:Autorecessive.svg This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Mutations in the chromosome 9q31 lead to a defective ABCA1 transporter. These mutations prevent the ABCA1 protein from effectively transporting cholesterol and phospholipids out of cells for pickup by ApoA1 in the bloodstream.

This inability to transport cholesterol out of cells leads to a deficiency of high-density lipoproteins in the circulation, which is a risk factor for coronary artery disease.

Additionally, the buildup of cholesterol in cells can be toxic, causing cell death or impaired function. These combined factors lead to the signs and symptoms of Tangier disease.

Epidemiology and Demographics

• Tangier disease is a rare disorder with approximately 50 cases identified worldwide.
• This disorder was originally discovered on Tangier Island off the coast of Virginia, but has now been identified in people from many different countries.

Diagnosis

High-density lipoproteins are created when a protein in the bloodstream, apolipoprotein A1 (apoA1), combines with cholesterol and phospholipids. The cholesterol and phospholipids used to form HDL originate from inside cells but is transported out of the cell into the blood via the ABCA1 transporter. People with Tangier disease have defective ABCA1 transporters resulting in a greatly reduced ability to transport cholesterol out of their cells, which leads to an accumulation of cholesterol in many body tissues. Reduced blood levels of high-density lipoproteins is sometimes described as hypoalphalipoproteinemia.

People affected by this condition also have slightly elevated amounts of fat in the blood (mild hypertriglyceridemia) and disturbances in nerve function (neuropathy). The tonsils are visibly affected by this disorder; they frequently appear orange or yellow and are extremely enlarged. Affected people often develop premature atherosclerosis, which is characterized by fatty deposits and scar-like tissue lining the arteries. Other signs of this condition may include an enlarged spleen (splenomegaly), an enlarged liver (hepatomegaly), clouding of the cornea, and early-onset cardiovascular disease.

External links

• Tangier disease at NLM Genetics Home Reference